You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 64 No. 10, October 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 •Correction
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Similar articles in this journal
 Topic Collections
 •Adolescent Psychiatry
 •Cognitive Therapy
 •Psychopharmacology
 •Suicide
 •Randomized Controlled Trial
 •Prognosis/ Outcomes
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

The Treatment for Adolescents With Depression Study (TADS)

Long-term Effectiveness and Safety Outcomes

The TADS Team

Arch Gen Psychiatry. 2007;64(10):1132-1143.

Context  The Treatment for Adolescents With Depression Study evaluates the effectiveness of fluoxetine hydrochloride therapy, cognitive behavior therapy (CBT), and their combination in adolescents with major depressive disorder.

Objective  To report effectiveness outcomes across 36 weeks of randomized treatment.

Design and Setting  Randomized, controlled trial conducted in 13 academic and community sites in the United States. Cognitive behavior and combination therapies were not masked, whereas administration of placebo and fluoxetine was double-blind through 12 weeks, after which treatments were unblinded. Patients assigned to placebo were treated openly after week 12, and the placebo group is not included in these analyses by design.

Participants  Three hundred twenty-seven patients aged 12 to 17 years with a primary DSM-IV diagnosis of major depressive disorder.

Interventions  All treatments were administered per protocol.

Main Outcome Measures  The primary dependent measures rated blind to treatment status by an independent evaluator were the Children's Depression Rating Scale–Revised total score and the response rate, defined as a Clinical Global Impressions–Improvement score of much or very much improved.

Results  Intention-to-treat analyses on the Children's Depression Rating Scale–Revised identified a significant time x treatment interaction (P < .001). Rates of response were 73% for combination therapy, 62% for fluoxetine therapy, and 48% for CBT at week 12; 85% for combination therapy, 69% for fluoxetine therapy, and 65% for CBT at week 18; and 86% for combination therapy, 81% for fluoxetine therapy, and 81% for CBT at week 36. Suicidal ideation decreased with treatment, but less so with fluoxetine therapy than with combination therapy or CBT. Suicidal events were more common in patients receiving fluoxetine therapy (14.7%) than combination therapy (8.4%) or CBT (6.3%).

Conclusions  In adolescents with moderate to severe depression, treatment with fluoxetine alone or in combination with CBT accelerates the response. Adding CBT to medication enhances the safety of medication. Taking benefits and harms into account, combined treatment appears superior to either monotherapy as a treatment for major depression in adolescents.

Trial Registration  clinicaltrials.gov Identifier: NCT00006286


Author Affiliations: The TADS Team Authors: The TADS is coordinated by the Department of Psychiatry and Behavioral Sciences and the Duke Clinical Research Institute at Duke University Medical Center, Durham, North Carolina, in collaboration with the NIMH. The Coordinating Center principal collaborators are John S. March, Susan Silva, Stephen Petrycki, John Curry, Karen Wells, John Fairbank, Barbara Burns, Marisa Domino, and Steven McNulty. The NIMH principal collaborators are Benedetto Vitiello and Joanne Severe. Principal investigators and coinvestigators from the clinical sites are as follows: Charles Casat, Jeanette Kolker, and Karyn Riedal (Carolinas Medical Center, Charlotte, North Carolina); Norah Feeny, Robert Findling, Sheridan Stull, and Susan Baab (Case Western Reserve University, Cleveland, Ohio); Elizabeth B. Weller, Michele Robins, Ronald A. Weller, and Naushad Jessani (The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania); Bruce Waslick (Baystate Health/Tufts University, Springfield, Massachusetts), Michael Sweeney, and Randi Dublin (Columbia University, New York, New York); John Walkup, Golda Ginsburg, Elizabeth Kastelic, and Hyung Koo (The Johns Hopkins University, Baltimore, Maryland); Christopher Kratochvil, Diane May, Randy LaGrone, and Brigette Vaughan (University of Nebraska, Omaha); Anne Marie Albano (Columbia University), Glenn S. Hirsch and Elizabeth Podniesinki (New York University, New York); Mark Reinecke, Bennett Leventhal, Gregory Rogers, and Rachel Jacobs (University of Chicago, Chicago, Illinois, and Northwestern University, Evanston, Illinois); Sanjeev Pathak, Jennifer Wells, Sarah Arszman, and Arman Danielyan (Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio); Paul Rohde, Anne Simons, James Grimm, and Stephenie Frank (University of Oregon, Eugene); Graham Emslie, Beth Kennard, Carroll Hughes, and Taryn L. Mayes (The University of Texas Southwestern Medical Center, Dallas); David Rosenberg, Nili Benazon, Michael Butkus, and Marla Bartoi (Wayne State University, Detroit, Michigan); and Kelly Posner, for the Columbia University Suicidality Classification Group. James Rochon (Duke Clinical Research Institute, Durham) is statistical consultant.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

RELATED LETTERS

Tailoring Treatment to Parental Values: A Comment on TADS
David Antonuccio
Arch Gen Psychiatry. 2008;65(6):723.
EXTRACT | FULL TEXT  

Tailoring Treatment to Parental Values: A Comment on TADS—Reply
John S. March and for the TADS Team
Arch Gen Psychiatry. 2008;65(6):723-724.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Screening for Child and Adolescent Depression in Primary Care Settings: A Systematic Evidence Review for the US Preventive Services Task Force
Williams et al.
Pediatrics 2009;123:e716-e735.
ABSTRACT | FULL TEXT  

Assessment of Safety and Long-Term Outcomes of Initial Treatment With Placebo in TADS
Kennard et al.
Am. J. Psychiatry 2009;166:337-344.
ABSTRACT | FULL TEXT  

Placebo Response in Randomized Controlled Trials of Antidepressants for Pediatric Major Depressive Disorder
Bridge et al.
Am. J. Psychiatry 2009;166:42-49.
ABSTRACT | FULL TEXT  

Core Components of Therapy in Youth: Do We Know what to Disseminate?
Weersing et al.
Behav Modif 2009;33:24-47.
ABSTRACT  

Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcus: In Reply
Gabbay et al.
Pediatrics 2009;123:e171-e173.
FULL TEXT  

Adolescents with SSRI-resistant depression: CBT plus antidepressant switch more effective than medication switch alone
Dubicka
Evid. Based Ment. Health 2008;11:110-110.
FULL TEXT  

Datapoints: Receipt of Psychotherapy by Adolescents Taking Antidepressants
Mark
Psychiatr. Serv. 2008;59:963-963.
FULL TEXT  

Patient Management Exercise Child and Adolescent Psychiatry
Levine and Albucher
Focus 2008;6:299-313.
ABSTRACT | FULL TEXT  

Bibliography for Child and Adolescent Psychiatry
Focus 2008;6:314-316.
FULL TEXT  

Abstracts: Child and Adolescent Psychiatry
Focus 2008;6:317-321.
FULL TEXT  

Fluoxetine Versus Placebo in Preventing Relapse of Major Depression in Children and Adolescents
Emslie et al.
Focus 2008;6:348-357.
ABSTRACT | FULL TEXT  

Tailoring Treatment to Parental Values: A Comment on TADS
Antonuccio
Arch Gen Psychiatry 2008;65:723-723.
FULL TEXT  

Tailoring Treatment to Parental Values: A Comment on TADS--Reply
March and for the TADS Team
Arch Gen Psychiatry 2008;65:723-724.
FULL TEXT  

Bringing a research base to psychiatry
Shuchman and Hebert
CMAJ 2008;178:1257-1258.
FULL TEXT  

Etablir une base de recherche en psychiatrie
Shuchman and Hebert
CMAJ 2008;178:1259-1260.
FULL TEXT  

Cost-Effectiveness of Depression Treatment for Adolescents
Norquist et al.
Am. J. Psychiatry 2008;165:549-552.
FULL TEXT  

Cost-Effectiveness of Treatments for Adolescent Depression: Results From TADS
Domino et al.
Am. J. Psychiatry 2008;165:588-596.
ABSTRACT | FULL TEXT  

Health advisories: when good intentions go bad
Mamdani
CMAJ 2008;178:1025-1026.
FULL TEXT  

Fluoxetine Versus Placebo in Preventing Relapse of Major Depression in Children and Adolescents
Emslie et al.
Am. J. Psychiatry 2008;165:459-467.
ABSTRACT | FULL TEXT  

Achievement and Maintenance of Sustained Response During the Treatment for Adolescents With Depression Study Continuation and Maintenance Therapy
Rohde et al.
Arch Gen Psychiatry 2008;65:447-455.
ABSTRACT | FULL TEXT  

Depression: Focus on the Adolescent Male
Breland and Park
Am J Mens Health 2008;2:87-93.
 

A Depressed Adolescent at High Risk of Suicidal Behavior
Vitiello and Pearson
Am. J. Psychiatry 2008;165:323-328.
FULL TEXT  

CBT plus an SSRI was as effective as an SSRI alone for adolescents with moderate to severe depression.
Kutcher
Evid. Based Med. 2008;13:13-13.
FULL TEXT  

Adding cognitive behavioural therapy to SSRIs does not improve outcomes in adolescents with major depression
Melvin
Evid. Based Ment. Health 2008;11:13-13.
FULL TEXT  

Bibliography for Major Depressive Disorder and Suicide
Focus 2008;6:58-62.
FULL TEXT  

Abstracts For Major Depressive Disorder and Suicide
Focus 2008;6:63-68.
FULL TEXT  

Child psychiatry and its relationship with the pharmaceutical industry: theoretical and practical issues
Timimi
Adv. Psychiatr. Treat. 2008;14:3-9.
ABSTRACT | FULL TEXT  

Effective Long-Term Treatment for Depressed Teens
JWatch Psychiatry 2007;2007:2-2.
FULL TEXT  

Suicide: scientific overview and relevance for trauma care providers
Crandall
Trauma 2007;9:213-220.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.